PDCD1 and neoplasm: Notably, combined treatment with pembrolizumab and chemotherapy was shown to enhance the pathologic complete response (pCR) and progression-free survival (PFS) of TNBC patients, suggesting that PD-1 mAb and chemotherapy may have a synergistic anti-tumor efficiency on TNBC patients16–18.